跳至主要内容
临床试验/CTRI/2021/06/034375
CTRI/2021/06/034375已完成4 期

on-Interventional Observational Study Assessing Safety And Efficacy Of Neutralizing Monoclonal Antibody (Casirivimab/ Imdevimab) Treatment In A Real-World-Setting Of Mild/Moderate Covid-19 Patients In India

Roche Products India Pvt Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. confirmed covid-19 infection
  • 2. Does not require oxygen
  • 3. Symptoms are mil/moderate
  • 4 At high risk for sever Covid 19 infection

排除标准

  • 1. hospitalized due to COVID-19
  • 2. Require oxygen therapy due to Covid-19
  • 3. Require an increase in baseline oxygen flow rate due to Covid-19

研究者

相似试验